Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon,Richard E. Pratley,Samuel Dagogo-Jack,James P. Mancuso,Susan Huyck,Urszula Masiukiewicz,Bernard Charbonnel,Robert C. Frederich,Silvina Gallo,Francesco Cosentino,Weichung J. Shih,Ira Gantz,Steven G. Terra,David Z.I. Cherney,Darren K. McGuire,Vertis-Cv Investigators

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

2020

Christopher P. Cannon
Richard E. Pratley
Samuel Dagogo-Jack
James P. Mancuso
Susan Huyck
Urszula Masiukiewicz
Bernard Charbonnel
Robert C. Frederich
Silvina Gallo
Francesco Cosentino
Weichung J. Shih
Ira Gantz
Steven G. Terra
David Z.I. Cherney
Darren K. McGuire
Vertis-Cv Investigators

Abstract Background The cardiovascular effects of ertugliflozin, an inhibitor of sodium–glucose cotransporter 2, have not been established. Methods In a multicenter, double-blind trial, we randomly...

Keywords:

Type 2 diabetes
Ertugliflozin
MEDLINE
cardiovascular outcomes
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

305

Citations